Immutep (IMMP) news
Recent news
Immutep Ltd: Maxim Group raises to buy from hold
Maxim Group has upgraded its rating for Immutep Ltd (IMMP) from "Hold" to "Buy," citing positive developments related to the company's key catalysts and valuation trends. The move reflects the firm's confidence in Immutep's progress in its LAG-3 immunotherapy programs and stabilization of the…
AInvest Wire · Jun 17, 2026Immutep raises A$90m from equity combo
Immutep raises A$90m from equity combo Immutep Limited (ASX:IMM), a clinical-stage biotech company specializing in the development of immune-modulating therapies, announced on [1] that it has successfully raised A$90 million through a combination of equity and institutional placements. This…
AInvest Wire · Jun 5, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.